



CrossRoads Extremity Systems, LLC
% Theresa Leister
Senior Consultant
Mrc X, LLC
6075 Poplar Avenue
Memphis, Tennessee 38119

August, 16, 2019

Re: K190722

Trade/Device Name: TriMAX™ Implant System

Regulation Number: 21 CFR 888.3030

Regulation Name: Single/Multiple Component Metallic Bone Fixation Appliances And Accessories

Regulatory Class: Class II

Product Code: JDR

Dated: April 8, 2019

Received: July 18, 2019

Dear Theresa Leister:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Vesa Vuniqui
Acting Assistant Director
DHT6A: Division of Joint Arthroplasty Devices
OHT6: Office of Orthopedic Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)

K190722

Device Name

TriMAX™ Implant System

Indications for Use (Describe)

The TriMAX™ Implant System is indicated for hand and foot bone fragment osteotomy fixation and joint arthrodesis.

Type of Use (Select one or both, as applicable)

☒ Prescription Use (Part 21 CFR 801 Subpart D)

☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510(k) Summary
TriMAX™ Implant System
July 17, 2019

Company: CrossRoads Extremity Systems, LLC
6055 Primacy Parkway, Suite 140
Memphis, TN 38119

**Establishment
Registration:** 3011421599

Primary Contact: Theresa Leister
Phone: 901-489-1715

Company Contact: Chad Hollis
Phone: 901-221-8406

Trade Name: TriMAX™ Implant System

Common Name: Staple, Fixation, Bone

Classification: Class II

Regulation Number: 21 CFR 888.3030 (Single/multiple component metallic bone fixation appliances and accessories)

Panel: 87- Orthopedic

Product Code: JDR

Predicate Devices: CrossRoads MotoCLIP™/HiMAX Implant System (K181410)
CrossRoads Screw System (K152072)
Stealth Staple (K153622 and K163440)

Device Description:

The TriMAX™ Implant System is a staple system which gives the surgeon a means of bone fixation in the management of bone fractures and reconstructive surgery. Prior to implantation, the legs of the implant are held substantially parallel to facilitate insertion into the prepared bone. Once implanted and released from the insertion device, the legs of the implant will move towards each other in a converging fashion. This movement creates compression across the adjoining bone members.

Indications for Use:

The TriMAX™ Implant System is indicated for hand and foot bone fragment osteotomy fixation and joint arthrodesis.

Substantial Equivalence:

The subject TriMAX™ Implant System components are substantially equivalent to the following predicate devices:

Primary Predicate: CrossRoads MotoCLIP™/HiMAX Implant System (K181410)

Secondary Predicate: CrossRoads Screw System (K152072)

Stealth Staple (K153622 & K163440)

The subject components are similar to the predicate devices in terms of indications, geometry, and materials. Mechanical analysis has shown the subject devices to be substantially equivalent in mechanical strength to the previously cleared CrossRoads MotoCLIP™/HiMAX Implant System (K181410) and the CrossRoads Screw System (K152072). Thus, it can be concluded that the subject devices raise no new questions of safety and effectiveness and are substantially equivalent to the predicate devices.

Performance Testing:

Theoretical analysis and mechanical testing was performed to confirm substantial equivalence of the subject TriMAX™ Implant System to the cited predicate. This analysis showed the subject device to be substantially equivalent in terms of performance to the predicate CrossRoads MotoCLIP™/HiMAX Implant System (K181410) and the CrossRoads Screw System (K152072). Thus, it was determined that no additional mechanical testing is required.

Additionally, pyrogen testing was completed to confirm that the TriMAX™ Implant System meets the endotoxin limit of 20 Endotoxin Units (EU)/Device.

Conclusion:

There are no substantial differences between the TriMAX™ Implant System and the predicate devices with respect to intended use and technological characteristics, including basic design, materials of manufacture, mechanical properties, and intended effect.

Therefore, the TriMAX™ Implant System is found to be substantially equivalent to the cited predicate, as it does not raise new questions of safety and effectiveness.